Cronos completes €57.5 million CanAdelaar acquisition; Dutch license decision pending
Cronos completed its acquisition of CanAdelaar B.V., a Dutch cannabis grower, on October 15, 2026, for a base price of €57.5 million plus contingent cash consideration tied to 2026 and 2027 Normalized EBITDA. The final Minister decision in a Bibob background review was still outstanding at closing, and an Addendum gives Cronos indemnities from seller Ring, subject to caps. The filing also shows CanAdelaar's Adjusted EBITDA declining from €24.2 million in the twelve months ended September 30, 2025 to €20.1 million annualized for the first half of 2026.
Key points
- Base purchase price of €57.5 million, subject to closing and post-closing adjustments, plus contingent consideration equal to 50% of CanAdelaar's 2026 and 2027 Normalized EBITDA
- Final Minister decision on the Bibob review was outstanding at closing; Ring indemnities cap liability at €22.5 million for the first two matters
- €12.5 million proposed DCMR odor penalty treated as indebtedness and deducted from the estimated closing price
- CanAdelaar Adjusted EBITDA was €20.1 million annualized for the six months ended June 30, 2026, versus €24.2 million for the twelve months ended September 30, 2025
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.